P W Vincent - JoVE Visualize

Showing results (1-10 of 12) with videos related to

Pageof 2

Sort By:

The Journal of Antimicrobial Chemotherapy|May 1, 1989

Comparative chemotherapeutic activity of new fluorinated 4-quinolones and standard agents against a variety of bacteria in a mouse infection modelJ C Sesnie, P W Fritsch, T J Griffin, et al.

Journal of Medicinal Chemistry|December 16, 1997

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.

International Journal of Radiation Oncology, Biology, Physics|January 1, 1992

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agentsJ S Sebolt-Leopold, P W Vincent, K A Beningo, et al.

Cancer Chemotherapy and Pharmacology|February 9, 2000

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.

Journal of Medicinal Chemistry|February 7, 2001

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functionsJ B Smaill, G W Rewcastle, J A Loo, et al.

Journal of Medicinal Chemistry|March 26, 1998

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.

Journal of Medicinal Chemistry|July 21, 2001

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.

Journal of Medicinal Chemistry|November 7, 2000

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinaseA M Thompson, C J Connolly, J M Hamby, et al.

Journal of Medicinal Chemistry|February 14, 1997

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.

Journal of Medicinal Chemistry|May 29, 1999

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.

Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:

Pageof 2

The Journal of Antimicrobial Chemotherapy|May 1, 1989

Comparative chemotherapeutic activity of new fluorinated 4-quinolones and standard agents against a variety of bacteria in a mouse infection modelJ C Sesnie, P W Fritsch, T J Griffin, et al.

Journal of Medicinal Chemistry|December 16, 1997

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.

International Journal of Radiation Oncology, Biology, Physics|January 1, 1992

Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agentsJ S Sebolt-Leopold, P W Vincent, K A Beningo, et al.

Cancer Chemotherapy and Pharmacology|February 9, 2000

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.

Journal of Medicinal Chemistry|February 7, 2001

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functionsJ B Smaill, G W Rewcastle, J A Loo, et al.

Journal of Medicinal Chemistry|March 26, 1998

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.

Journal of Medicinal Chemistry|July 21, 2001

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptorJ B Smaill, H D Showalter, H Zhou, et al.

Journal of Medicinal Chemistry|November 7, 2000

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinaseA M Thompson, C J Connolly, J M Hamby, et al.

Journal of Medicinal Chemistry|February 14, 1997

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congenersH D Showalter, A D Sercel, B M Leja, et al.

Journal of Medicinal Chemistry|May 29, 1999

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptorJ B Smaill, B D Palmer, G W Rewcastle, et al.

Pageof 2